Outcome prognostic factors in inoperable malignant bowel obstruction

被引:9
|
作者
Romeo, Margarita [1 ,2 ]
de los LLanos Gil, Maria [1 ]
Cuadra Urteaga, Jose Luis [1 ]
Vila, Laia [1 ]
Ahlal, Sara [1 ]
Indacochea, Alberto [1 ,3 ]
Pardo, Nuria [1 ,4 ]
Radua, Joaquim [5 ,6 ]
Font, Albert [1 ]
Tuca, Albert [7 ]
机构
[1] Inst Catala Oncol, Dept Med Oncol, Carretera Canyet S-N, Badalona 08916, Spain
[2] Univ Autonoma Barcelona, Barcelona, Spain
[3] Vall dHebron Inst Recerca, CRG, Barcelona, Spain
[4] Hosp Valle De Hebron, Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain
[5] FIDMAG Germanes Hosp CIBERSAM, St Boi De Llobregat, Spain
[6] Karolinska Inst, Dept Clin Neurosci, Ctr Psychiat Res, Solna, Sweden
[7] Hosp Clin Barcelona, Dept Med Oncol, Support Care Canc Unit, Barcelona, Spain
关键词
Malignant bowel obstruction; Octreotide; Hyoscine butylbromide; Prognostic factors; SCOPOLAMINE BUTYLBROMIDE; DOUBLE-BLIND; PHARMACOLOGICAL-TREATMENT; HYOSCINE BUTYLBROMIDE; RANDOMIZED-TRIAL; SYMPTOM CONTROL; CLINICAL-TRIAL; OCTREOTIDE; CANCER; MANAGEMENT;
D O I
10.1007/s00520-016-3299-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inoperable malignant bowel obstruction (MBO), a severe complication of peritoneal carcinomatosis, has a low desobstruction rate (30-40 %) and end-of-life decision-making is hampered by the lack of known prognostic factors. This study aimed to explore prognostic factors for desobstruction in MBO. All patients with inoperable MBO admitted in our large oncology hospital between 2010 and 2013 were treated following a clinical protocol based on antiemetics, steroids and two antisecretories, octreotide, and hyoscine butylbromide. Two prognostic factor analyses using logistic regressions were performed, one based on data from day 1 of admission and the other on data from day 8. Forty-five patients were included. Frequency of desobstruction was 48.9 %. In the analysis of prognostic factors on day 1, MBO episodes derived from functional physiopathologic mechanisms (vs. mechanic or mixed) were more prone to resolve (p < 0.001 corrected for multiple comparisons). Considering patients alive with persistent obstruction on day 8, a better clinical condition was the variable more associated with desobstruction, but without statistical significance after correction for multiple comparisons. A functional physiopathologic mechanism of MBO development may be an early prognostic factor for desobstruction. A high proportion of desobstruction was observed, suggesting that the combination of antisecretories with different mechanism of action warrants further investigation.
引用
收藏
页码:4577 / 4586
页数:10
相关论文
共 50 条
  • [31] Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction
    Mercadante, S
    Ripamonti, C
    Casuccio, A
    Zecca, E
    Groff, L
    SUPPORTIVE CARE IN CANCER, 2000, 8 (03) : 188 - 191
  • [32] Epidemiology, risk factors, and outcomes in malignant bowel obstruction.
    Vieito, Maria
    Lago, Nieves Martinez
    Campos, Marta Carmona
    Lopez, Carmela Rodriguez
    Baron, Francisco J.
    Candamio, Sonia
    Neto, Isabel Galrisa
    Lopez, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?
    Hoppenot, Claire
    Peters, Pamela
    Cowan, Matthew
    Moore, Elena Diaz
    Hurteau, Jean
    Lee, Nita Karnik
    Yamada, S. Diane
    GYNECOLOGIC ONCOLOGY, 2019, 154 (01) : 177 - 182
  • [34] Prognostic factors of survival in patients with inoperable distal malignant biliary strictures.
    Prat, F
    Chapat, O
    Ducot, B
    Pelletier, G
    Ponchon, T
    Fritsch, J
    Buffet, C
    GASTROENTEROLOGY, 1997, 112 (04) : A521 - A521
  • [35] Nutritional Status as a Prognostic Factor for Survival in Palliative Care: A Retrospective Observational Analysis of Home Parenteral Nutrition in Cancer Patients with Inoperable Malignant Bowel Obstruction
    Tenderenda, Karolina
    Gierczak, Aleksandra
    Panczyk, Mariusz
    Sobocki, Jacek
    Zaczek, Zuzanna
    NUTRIENTS, 2024, 16 (11)
  • [36] Cost-effectiveness of management strategies for patients with recurrent ovarian cancer and inoperable malignant bowel obstruction
    Peters, Pamela N.
    Moyett, Julia M.
    Davidson, Brittany A.
    Cantrell, Sarah
    Bliss, Sara E.
    Havrilesky, Laura J.
    GYNECOLOGIC ONCOLOGY, 2022, 167 (03) : 523 - 531
  • [37] Cost-effectiveness of management strategies for patients with recurrent ovarian cancer and inoperable malignant bowel obstruction
    Peters, Pamela
    Bliss, Sara
    Davidson, Brittany
    Havrilesky, Laura
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S54 - S54
  • [38] Management of malignant bowel obstruction
    Ripamonti, Carla Ida
    Easson, Alexandra M.
    Gerdes, Hans
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (08) : 1105 - 1115
  • [39] Prognostic CT findings of malignant bowel obstruction in patients with advanced ovarian cancer
    Micco, Maura
    Sbarra, Martina
    Gui, Benedetta
    Bianco, Nicola Carlo
    Rodolfino, Elena
    Manfredi, Riccardo
    TUMORI JOURNAL, 2020, 106 (02): : 149 - 154
  • [40] MALIGNANT LARGE BOWEL OBSTRUCTION
    PHILLIPS, RKS
    HITTINGER, R
    FRY, JS
    FIELDING, LP
    BRITISH JOURNAL OF SURGERY, 1985, 72 (04) : 296 - 302